Bionano Genomics to Support Largest Study to Date on COVID-19 Disease Susceptibility
Bionano Genomics, Inc. (BNGO)
Last bionano genomics, inc. earnings: 8/8 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today the launch of the largest study to date aiming to identify genomic variants and novel active substances that influence resistance or sensitivity to the SARS-CoV2 virus, or COVID-19, disease progression and drug response. A variety of genomic and other biological variables will be compared between those patients who show no or mild symptoms and those who show severe illness. The study will control for viral strain differences, and for the known risk factors of age and chronic illness such as heart disease, diabetes, or other immune-compromising disease. The first study of this kind is underway in Wuhan, China, and is being performed at the site of Wuhan-based GrandOmics, a service provider using Bionano technology. Now, the Hannover Medical School is launching a study involving 1,000 patients and controls, consisting of COVID-19 patients and their partners and first-degree relatives
Show less
Read more
Impact Snapshot
Event Time:
BNGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNGO alerts
High impacting Bionano Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
BNGO
News
- Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis [Yahoo! Finance]Yahoo! Finance
- Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor AnalysisGlobeNewswire
- Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal [Yahoo! Finance]Yahoo! Finance
- Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy ProposalGlobeNewswire
- Bionano Announces Presentations at the American Society of Hematology (ASH) Annual Meeting that Underscore OGM Utility Across Blood Cancer Research and Cell & Gene Therapy [Yahoo! Finance]Yahoo! Finance
BNGO
Analyst Actions
- 11/15/24 - Ladenburg Thalmann
BNGO
Sec Filings
- 12/19/24 - Form DEFA14A
- 12/5/24 - Form DEFA14A
- 12/5/24 - Form DEF
- BNGO's page on the SEC website